Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC (KEYVIBE-006)

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502752-31-00

Acronym

MK-7684A-006

Enrollment

Registered

2023-09-11

Start date

2022-04-29

Completion date

Unknown

Last updated

2025-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Brief summary

Per protocol amendment 4, there are no primary or secondary endpoints

Interventions

DRUGDURVALUMAB

DRUGCISPLATIN

DRUGCARBOPLATIN

DRUGEto-GRY® 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGALIMTA 500 mg powder for concentrate for solution for infusion

DRUGMK-7684A

DRUGPEMETREXED

DRUGPACLITAXEL

DRUGETOPOSIDE

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Per protocol amendment 4, there are no primary or secondary endpoints	—

Countries

Austria, Croatia, Czechia, France, Germany, Greece, Italy, Poland, Portugal, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026